A View From The NEI – Ophthalmic Innovation in 2014

The National Eye Institute (NEI) spends $675 million annually, mostly on basic science and discovery research. In addition, said Matthew J. McMahon, PhD, Director of the agency’s Office of Translational Research, “We have a clear mandate to help translate these discoveries into clinical medicine and public health improvements.” He points to the agency’s role in…

Read More

Avalanche Biotechnologies Gives Ocular BioFactory Tour

Thomas W. Chalberg, PhD presented an update on Avalanche Biotechnologies Inc.’s pipeline of products emerging from its integrated gene therapy discovery, development, and manufacturing platform, Ocular BioFactory. Avalanche’s lead product, AVA-101, is undergoing Phase IIa clinical trials for wet AMD; the company could submit an investigational new drug applications in the second half of 2015.…

Read More

Eleven Biotherapeutics

Presenter: Abbie C. Celniker, PhD Dr. Celniker brings more than 20 years of proven protein therapeutic expertise to Eleven Biotherapeutics. Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, which was acquired by Alexion Pharmaceuticals. View Full Profile

Read More

Eleven Biotherapeutics Gets to the Root of Ophthalmic Diseases

Eleven Biotherapeutics – Abbie Celniker, CEO for Eleven Biotherapeutics, provides the audience at the 5th Annual Ophthalmology Innovation Summit with an update on her company’s progress over the past year. Highlighting their company’s focus on understanding the biology of key targets in ophthalmic diseases and creating protein therapeutics to treat them, Abbie details the current…

Read More